"Breakthrough" Devices May Avoid OIG Medicare Fraud Exclusion
This article was originally published in The Gray Sheet
HHS may be inclined to exempt manufacturers of novel medical devices and drugs from its newly articulated policy of excluding "indirect" health care providers convicted of Medicare fraud, attorney Helen Trilling from the Washington, D.C. law firm of Hogan & Hartson suggested at a recent Food & Drug Law Institute meeting.
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.